[Clinical pharmacokinetics of vinca alkaloids].
Vinca alkaloids (VA) represent a family of closely related molecules, which includes vincristine (VCR), vinblastine (VLB), vindesine (VDS) and navelbine (NVB), a new synthetic VA presently in phase II clinical trial. Development of sensitive and specific analytical tools (polyclonal and monoclonal antibodies) enabled us to investigate the kinetic behavior of VDS and NVB after IV bolus or long term administration. Following IV bolus injection, the mean pharmacokinetic parameters are: total plasma clearance: 0.53 l/h-1kg-1, 0.72 l/h-1kg-1 and apparent elimination half-life: 23.2 h, 39.5 h for VDS and NVB, respectively. Chronic treatment reveals time- and dose-dependence relationships and detailed observations of individual kinetics demonstrate an important interindividual variability for both drugs. Renal excretion of VDS and NVB is low (from 5 to 12% of the total dose), suggesting the important role of the liver in their rapid elimination.
Rahmani
R
R
INSERM U 278, Faculté de Pharmacie, Marseille, France.
Samak
R
R
Bore
P
P
Cano
J P
JP
D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D006801:Humans; D007275:Injections, Intravenous; D009369:Neoplasms / Q000378:metabolism; D013997:Time Factors; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D014751:Vindesine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000077235:Vinorelbine
D000970:Antineoplastic Agents; D014747:Vinblastine; D000077235:Vinorelbine; D014751:Vindesine
Pharmacocinétique clinique des vinca-alcaloïdes.